Search Result

Results for "

IFN-γ secretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (1) Apoptosis (2) C-type Lectin-like Receptors (CTLRs) (1) CCR (1) CD1 (1) Cytochrome P450 (1) E1/E2/E3 Enzyme (1) Galectin (1) HIV (1) IFNAR (7) Interleukin Related (8) Isotope-Labeled Compounds (1) LAG-3 (1) Lipoxygenase (1) MAP4K (1) NF-κB (1) Parasite (2) PARP (2) PD-1/PD-L1 (9) Phosphatase (2) PI3K (1) PTEN (2) TNF Receptor (2) Toll-like Receptor (TLR) (2) Transmembrane Glycoprotein (2)
By Research Areas:	Cancer (23) Infection (3) Inflammation/Immunology (13) Metabolic Disease (2)

By Targets:

Adenosine Receptor (1)

Akt (1)

Apoptosis (2)

C-type Lectin-like Receptors (CTLRs) (1)

CCR (1)

CD1 (1)

Cytochrome P450 (1)

E1/E2/E3 Enzyme (1)

Galectin (1)

HIV (1)

IFNAR (7)

Interleukin Related (8)

Isotope-Labeled Compounds (1)

LAG-3 (1)

Lipoxygenase (1)

MAP4K (1)

NF-κB (1)

Parasite (2)

PARP (2)

PD-1/PD-L1 (9)

Phosphatase (2)

PI3K (1)

PTEN (2)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

Transmembrane Glycoprotein (2)

By Research Areas:

Cancer (23)

Infection (3)

Inflammation/Immunology (13)

Metabolic Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136339

Cbl-b-IN-1 1 Publications Verification	E1/E2/E3 Enzyme Interleukin Related	Inflammation/Immunology Cancer
Cbl-b-IN-1 (Example 519) is an inhibitor of Cbl-b, with an IC₅₀ of less than 100 nM. Cbl-b-IN-1 can promote the secretion of cytokines such as IL-2, IFN-γ, and TNF-α, facilitate T cell activation, and enhance the TCR signaling pathway. Cbl-b-IN-1 can be used in research on immunomodulation .

HY-162727

GCS-12	IFNAR Interleukin Related CD1	Inflammation/Immunology Cancer
GCS-12 is a Th1/2-balanced sulfonamide glycolipid with improved interaction with CD1d. GCS-12 is an agonist for natural killer T (NKT) cell, that induces the secretion of cytokine IFN-γ and IL-4, and exhibits immunomodulatory and anti-tumor activities in mice .

HY-173464

PD-1/PD-L1-IN-55	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC₅₀ of 4.8 nM. PD-1/PD-L1-IN-55 promotes IFN-γ secretion and reduces the proportion of PD-L1 late apoptosis .

HY-168078

PD-1/PD-L1-IN-50	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-50 (Compound LG-12) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + T cell activation, and activates the antitumor immunity of T cells .

HY-149356

PD-1/PD-L1-IN-31	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC₅₀=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .

HY-P991353

Sym-021	PD-1/PD-L1	Cancer
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .

HY-176814

LAG-3-IN-1	LAG-3	Cancer
LAG-3-IN-1 (Compound 11) is a LAG-3 inhibitor with a K_D of 0.41  μM. LAG-3-IN-1 disrupts the LAG-3/MHCII interaction, enhances IFN-γ secretion and promotes tumor cell killing in cocultures of PBMCs and cancer cells. LAG-3-IN-1 can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .

HY-P991475

MG-1131	Transmembrane Glycoprotein NF-κB IFNAR	Cancer
MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase *IFN-γ* secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-173180

5-LOX-IN-8	Lipoxygenase Interleukin Related TNF Receptor IFNAR	Inflammation/Immunology
5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD) .

HY-P99159

Ivuxolimab	Interleukin Related	Cancer
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 ⁺ and CD8 ⁺ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as *IFN-γ, IL-2) secretion*, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .

HY-162644

Antitumor agent-170	PD-1/PD-L1 PARP	Cancer
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC₅₀ of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a K_i of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics .

HY-162643

Antitumor agent-169	PD-1/PD-L1 PARP	Cancer
Antitumor agent-169 (Compound B3) is a dual inhibitor PD-1/PD-L1 interaction and PARP7, with IC₅₀s of 0.426 μM and 2.50 nM. Antitumor agent-169 exhibits an affinity to human PD-L1, with K_i of 20.2 nM. Antitumor agent-169 restores the T cell function, increases IFN-γ secretion. Antitumor agent-169 inhibits cell viability of MDA-MB-231 and Jurkat T, exhibits antitumor efficacy against melanoma in mouse model and good pharmacokinetic characteristics .

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

HY-176755

CCL-34	Toll-like Receptor (TLR)	Inflammation/Immunology
CCL-34 is a Toll-like receptor 4 (TLR4) activator. CCL-34 significantly induced dendritic cell (DC) CD83 expression and IL-12p70 production in a dose-dependent manner, thereby inducing DC maturation. CCL-34 enhanced the allostimulatory activity of DC on naive CD4+CD45+RA+ T cell proliferation and IFN-γ secretion. CCL-34 further induced antigen presentation ability in mice inoculated with doxorubicin-treated colorectal cancer cells. CCL-34 can be used in studies of immune stimulation.

HY-175195

Adenosine receptor antagonist 6	Adenosine Receptor Interleukin Related IFNAR Cytochrome P450	Inflammation/Immunology Cancer
Adenosine receptor antagonist 6 is an orally active and selective A_2A adenosine receptor (A_2AAR) antagonist, with a K_i of 19.18 nM. Adenosine receptor antagonist 6 inhibits 5’-N-ethylcarboxamide adenosine (NECA) (HY-103173)-mediated cAMP production (IC₅₀ = 0.089 μM) and immunosuppression, while promoting IL-2 and *IFN-γ* secretion. Adenosine receptor antagonist 6 abolishes the immunosuppressive effects of adenosine on T-cell activation and cytokine release. Adenosine receptor antagonist 6 inhibits tumor growth in a CT26/MC38 xenograft model. Adenosine receptor antagonist 6 can be used for the study of colon cancer .

HY-D1056C1

Lipopolysaccharides, from S. enterica serotype enteritidis LPS, from Salmonella enterica (Serotype enteritidis)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype enteritidis are lipopolysaccharide endotoxins and TLR-4 activators derived from the enteritidis serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype enteritidis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype enteritidis can induce systemic inflammatory responses, increasing levels of TNF-α, IFN-γ, IL-6, IL-10, and nitrate in plasma . It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.

HY-P990242

Anti-Mouse Galectin-9 Antibody (RG9-1)	Galectin TNF Receptor IFNAR Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of *IFN-γ, TNF-α, and IL-6*. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 ⁺ and CD8 ⁺ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .

HY-P991610

S-095029 Sym025	C-type Lectin-like Receptors (CTLRs)	Cancer
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .

HY-159892

PD-1/PD-L1-IN-54	PD-1/PD-L1 IFNAR Interleukin Related PI3K Akt	Cancer
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8 ⁺ T cells, upregulating PD-1 expression, and increasing secretion of *IFN-γ* and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1 .

HY-P990297

Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) 1 Publications Verification	CCR HIV	Infection Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .

HY-136065

bpV(phen) 2 Publications Verification	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

HY-122818

BpV(phen) trihydrate 2 Publications Verification Bisperoxovanadium(phen) trihydrate	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
BpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. BpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). BpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

HY-P990855

Anti-CD8α Antibody (OKT-8)	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 ⁺ T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .

Cat. No.	Product Name	Type

HY-D1056C1

Lipopolysaccharides, from S. enterica serotype enteritidis LPS, from Salmonella enterica (Serotype enteritidis)	Carbohydrates
Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype enteritidis are lipopolysaccharide endotoxins and TLR-4 activators derived from the enteritidis serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype enteritidis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype enteritidis can induce systemic inflammatory responses, increasing levels of TNF-α, IFN-γ, IL-6, IL-10, and nitrate in plasma . It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.

Lipopolysaccharides, from S. enterica serotype enteritidis

LPS, from Salmonella enterica (Serotype enteritidis)

Carbohydrates

Lipopolysaccharides, from S. enterica (Salmonella enterica) serotype enteritidis are lipopolysaccharide endotoxins and TLR-4 activators derived from the enteritidis serotype of S. enterica, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. enterica serotype enteritidis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from S. enterica serotype enteritidis can induce systemic inflammatory responses, increasing levels of TNF-α, IFN-γ, IL-6, IL-10, and nitrate in plasma .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.

Cat. No.	Product Name	Target	Research Area